Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT07198165 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07198165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07198165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-Course Radiotherapy Combined With CAPOX and Bevacizumab, With or Without PD-1 Inhibitors, as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 5, 2025
Completion date
December 31, 2030
Enrollment
104 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemoradiotherapy, immunotherapy, rectal adenocarcinoma, rectal cancer, rectal cancer patients, rectal cancer, radiotherapy, targeted therapy, total neoadjuvant therapy, total neoadjuvant treatment